Over the last decade, several anti-angiogenic agents targeting on VEGF have been approved by FDA for the treatment of cancers, such as VEGF inhibitor bevacizumab (Avastin®), small-molecule RTK (receptor tyrosine kinase) inhibitor sorafenib (Nexavar®) and sunitinib (Sutent®), monoclonal antibody against VEGF receptor pazopanib (Votrient®) [13]. The gene discussed is VEGFA; the disease is cancer.